Paul Tudor Jones Arcutis Biotherapeutics, Inc. Transaction History
Tudor Investment Corp Et Al
- $15.5 Billion
- Q1 2024
A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 204,779 shares of ARQT stock, worth $1.9 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
204,779Holding current value
$1.9 Million% of portfolio
0.01%Shares
4 transactions
Others Institutions Holding ARQT
# of Institutions
172Shares Held
126MCall Options Held
498KPut Options Held
1.64M-
Jennison Associates LLC12.2MShares$113 Million0.08% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA8.79MShares$81.7 Million4.57% of portfolio
-
State Street Corp Boston, MA8.78MShares$81.7 Million0.0% of portfolio
-
Suvretta Capital Management, LLC New York, NY7.88MShares$73.3 Million3.34% of portfolio
-
Rubric Capital Management LP New York, NY7.51MShares$69.8 Million2.54% of portfolio
About Arcutis Biotherapeutics, Inc.
- Ticker ARQT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,187,500
- Market Cap $560M
- Description
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...